We postulate that the rate of dual IDH1/2 mutations in gliomas is underestimated, due to the use of IDH1 R132H immunohistochemistry, and anticipate that its detection will increase with the more widespread use of NGS technologies in cancer diagnosis. The gene discussed is IDH1; the disease is cancer.